Five landmark clinical studies were published on glycosylated fibronectin as a new biomarker and rapid point-of-care test for risk assessment of preeclampsia

/ Uncategorized / By Diabetomics

Sokratous, N., Wright, A., Syngelaki, A., Kakouri, E., Laich, A. and Nicolaides, K.H. (2023), Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks’ gestation. Ultrasound Obstet Gynecol. Accepted Author Manuscript.

Sokratous, N., Bednorz, M., Syngelaki, A., Wright, A., Nicolaides, K.H. and Kametas, N.A. (2023), Prediction of superimposed pre-eclampsia by serum glycosylated fibronectin and angiogenic factors in women with chronic hypertension. Ultrasound Obstet Gynecol. Accepted Author Manuscript

Sokratous, N., Bednorz, M., Sarli, P., Morillo Montes, O.E., Syngelaki, A., Wright, A. and Nicolaides, K.H. (2023), Screening for pre-eclampsia by maternal serum glycosylated fibronectin at 11−13 weeks’ gestation. Ultrasound Obstet Gynecol, 62: 504-511. https://doi.org/10.1002/uog.26303

Sokratous, N., Bednorz, M., Wright, A., Nicolaides, K.H. and Kametas, N.A. (2023), Prediction of imminent pre-eclampsia by serum glycosylated fibronectin in women with new onset hypertension. Ultrasound Obstet Gynecol, 62: 653-659. https://doi.org/10.1002/uog.27458

Moungmaithong, S., Wang, X., Lau, C.S.L., Tse, A.W.T., Lee, N.M.W., Leung, H.H.Y., Poon, L.C. and Sahota, D.S. (2023), Glycosylated fibronectin improves first trimester prediction of pre-eclampsia. Ultrasound Obstet Gynecol, 62: 512-521. https://doi.org/10.1002/uog.27451